Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario–(Newsfile Corp.
Pending Health Canada and FDA regulatory approval, light-activated Ruvidar® represents a potentially transformative, bladder-sparing treatment option for patients with limited alternatives, addressing ...
4don MSN
Can colorblindness lead to worse outcomes for bladder cancer patients? A new study suggests so
The earliest symptoms of bladder cancer may go unnoticed by patients with colorblindness or similar color vision deficiencies ...
Novo Nordisk (NVO) stock is set to outperform Eli Lilly (LLY) stock thanks mainly to a strong commercial rollout for the company's Wegovy pill. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results